Investigational MIGS device could minimize fibrotic response

The first human clinical trial to evaluate the MINIject glaucoma device has finished enrolling participants, according to a press release from developers iSTAR Medical.
Source: Daily Dose of Eye Care

https://www.lvcenter4sight.com/investigational-migs-device-could-minimize-fibrotic-response/

Comments

Popular posts from this blog

AGTC Announces Topline Interim Six-Month Data of XLRS Gene Therapy from Ongoing Phase 1/2 Clinical Trial

What to Know About Resveratrol

The Hidden Perils of Eye Rubbing